COVID-19 lockdown and lifestyles: A narrative review.

COVID-19 lockdown and lifestyles: A narrative review.

Publication date: Sep 23, 2024

The primary objective worldwide during the coronavirus disease 2019 (COVID-19) pandemic had been controlling disease transmission. However, lockdown measures used to mitigate transmission affected human behavior and altered lifestyles, with a likely impact on chronic non-communicable diseases. More than a year into the pandemic, substantial peer-reviewed literature emerged on altered lifestyles following the varying lockdown measures imposed globally to control the virus spread. We explored the impact of lockdown measures on six lifestyle factors, namely diet, physical activity, sleep, stress, social connectedness, and the use of tobacco, alcohol, or other harmful substances. We comprehensively searched PubMed and the World Health Organization’s global literature database on COVID-19 and retrieved 649 relevant articles for the narrative review. A critical interpretative synthesis of the articles was performed. Most of the articles included in the review identified the negative effect of lockdown measures on each of the lifestyle factors in many parts of the world. Encouraging lifestyle trends were also highlighted in a few articles. Such trends can positively influence the outcome of lifestyle-related chronic diseases, such as obesity and diabetes. The lockdown associated with COVID-19 has largely had a negative impact on the lifestyles of individuals and communities across many countries and cultures. However, some individuals and communities also initiated positive lifestyle-related behavioral changes. If the knowledge generated by studying the impact of COVID-19-related lockdowns on the six lifestyle factors is further consolidated, it could improve chronic disease outcomes. This will help better understand lifestyle behaviors amidst crises and assist in redesigning extreme public health measures such as lockdowns. . It is up to governments, communities, and healthcare/academic entities to derive benefit from lessons learned from the pandemic, with the ultimate objective of better educating and promoting healthy lifestyles among communities.

Open Access PDF

Concepts Keywords
Coronavirus Alcohol
Diabetes COVID-19
F1000res COVID-19
Healthy Diet
Lockdowns Diet
Emotional well-being
Exercise
Humans
Life Style
Lifestyle
Pandemics
Physical activity
Quarantine
SARS-CoV-2
Sleep
Smoking
Social connectedness
Stress
Stress, Psychological
Substance

Semantics

Type Source Name
disease MESH COVID-19
disease MESH lifestyles
disease MESH non-communicable diseases
drug DRUGBANK Ethanol
disease MESH chronic diseases
disease MESH obesity
drug DRUGBANK Tropicamide
drug DRUGBANK Coenzyme M
pathway REACTOME Reproduction
disease IDO country
disease MESH anxiety
disease MESH substance abuse
disease MESH plant based diet
disease MESH weight gain
disease MESH overweight
disease MESH sedentary lifestyle
disease MESH eating disorders
disease MESH psychiatric disorders
disease IDO facility
disease IDO site
disease MESH home environments
drug DRUGBANK Etoperidone
disease MESH insomnia
disease MESH depression
disease MESH sleepiness
disease MESH loneliness
disease MESH daytime sleepiness
disease MESH emergency
disease MESH relapse
disease IDO intervention
drug DRUGBANK Medical Cannabis
disease MESH post traumatic stress disorders
drug DRUGBANK Pentaerythritol tetranitrate
disease IDO contact tracing
disease MESH infection
disease MESH suicidal ideation
disease MESH suicide
drug DRUGBANK Silver
disease MESH neurodevelopmental disorders
disease MESH psychological distress
drug DRUGBANK Creatinolfosfate
disease MESH violence
disease IDO quality
disease MESH malnutrition
disease MESH metabolic syndrome
disease IDO blood
drug DRUGBANK Melatonin
disease MESH liver cirrhosis
drug DRUGBANK Isoxaflutole
disease MESH tic
disease MESH infectious disease
pathway REACTOME Infectious disease
drug DRUGBANK Guanosine
disease MESH convergence insufficiency
drug DRUGBANK Trestolone
drug DRUGBANK Haloperidol
drug DRUGBANK Vorinostat
drug DRUGBANK Nicotine
disease MESH Cardiovascular Diseases
disease MESH cognitive impairment
disease IDO process
disease MESH cystic fibrosis
disease MESH Cyst
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH Death
drug DRUGBANK Troleandomycin
disease MESH Diabetes Complications
disease MESH Syndromes
disease MESH intellectual disabilities
disease MESH multiple sclerosis
disease MESH respiratory diseases
disease IDO replication
disease MESH Dementia
disease MESH Stress Psychological

Original Article

(Visited 3 times, 1 visits today)